VMD Sciences Supports Veterinary Oncologist with Access to Advanced Cancer Treatment for Dog Through Global Managed Access
VMD Sciences, the leader in global veterinary pharmaceutical access services, announced the successful, compliant importation by a U.S. licensed veterinarian of an advanced cancer therapy approved in Europe. The specialized tyrosine kinase inhibitor unavailable in the U.S. was for the treatment of Jetta, an 8-year-old mixed-breed dog battling metastatic mast cell cancer. Through their Managed Access Program (MAP), VMD Sciences supported Dr. Seth Glasser, DVM, DipACVIM (Oncology) at Garden State Veterinary Specialists in New Jersey through the complex regulatory process and ultimate fulfillment of the specialized treatment.
VMD Sciences Supports Community Veterinary Oncologist in Securing Novel Treatment for Dog with Inoperable Cancer
VMD Sciences, the global leader in veterinary regulatory pharmaceutical services, played a pivotal role in helping a community veterinarian access an experimental treatment for a dog whose life-threatening soft tissue sarcoma was deemed inoperable. This success story highlights the potential of utilizing legislated regulatory pathways in veterinary medicine, a burgeoning field that offers hope for animals with serious health conditions where no other options are available.
